8-K – 2026-05-20 – amgn-20260519.htm

8-K

0000318154 false 0000318154 2026-05-19 2026-05-19

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2026

 
 
Amgen Inc.
(Exact name of Registrant as Specified in Its Charter)
 
 

Delaware

001-37702

95-3540776

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One Amgen Center Drive

 

Thousand Oaks , California

 

91320-1799

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (805) 447-1000

 

 

(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common stock, $0.0001 par value

 

AMGN

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

Item 5.07 Submission of Matters to a Vote of Security Holders.
The Company held its Annual Meeting on May 19, 2026. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:
Item 1 - Election of Directors
Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company’s 2027 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.
 

Name

Votes For

Votes Against

Abstain

Broker
Non-Votes

Dr. Wanda M. Austin

408,261,366

4,136,960

541,141

63,739,635

Mr. Robert A. Bradway

390,137,618

20,492,559

2,309,290

63,739,635

Dr. Michael V. Drake

407,302,029

4,797,875

839,563

63,739,635

Dr. Brian J. Druker

409,304,364

3,054,075

581,028

63,739,635

Mr. Robert A. Eckert

393,137,908

19,206,011

595,548

63,739,635

Mr. Greg C. Garland

390,923,223

21,425,903

590,341

63,739,635

Mr. Charles M. Holley, Jr.

402,699,984

9,642,231

597,252

63,739,635

Dr. S. Omar Ishrak

408,204,077

4,139,152

596,238

63,739,635

Dr. Tyler Jacks

400,237,518

12,117,252

584,697

63,739,635

Dr. Mary E. Klotman

407,732,503

4,398,737

808,227

63,739,635

Ms. Ellen J. Kullman

405,340,175

6,775,403

823,889

63,739,635

Ms. Amy E. Miles

406,709,817

5,385,886

843,764

63,739,635

 
Item 2 - Advisor y Vote to A pprove Our Executive Compensation
The advisory vote to approve our executive compensation was approved.
 

 For:

399,315,381

 Against:

11,987,682

 Abstain:

1,636,404

 Broker Non-Votes:

63,739,635

 
Item 3 - Ratification of Selection of Inde pendent Re gistered Public Accountants
Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2026. No Broker Non-Votes resulted from the vote on this proposal.
 

 For:

447,904,443

 Against:

28,209,748

 Abstain:

564,911

 
Item 4 - Stockholder Proposal to Require an Independent Board Chairman
The stockholder proposal to require an independent board chairman was not approved.
 

 For:

72,902,413

 Against:

338,465,655

 Abstain:

1,571,399

 Broker Non-Votes:

63,739,635

 
No other matters were submitted for stockholder action.
 

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AMGEN INC.

 

 

 

 

Date:

May 20, 2026

By:

/s/ Jonathan P. Graham

 

 

 

Name: Jonathan P. Graham

 

 

 

Title:	Executive Vice President and General Counsel and Secretary